Literature DB >> 24615145

Preparation of przewalskinic acid A from salvianolic acid B using a crude enzyme from an Aspergillus oryzae strain.

Chunying Liu1, Yinghua Jin, Hongshan Yu, Changkai Sun, Shuiping Zhou, Yonghong Zhu, Longquan Xu, Chong Yu, Fengxie Jin.   

Abstract

Przewalskinic acid A is a rare, water-soluble, and highly biologically active ingredient found, thus far, only in the Salvia przewalskii Maxim herb; however, the content in S. przewalskii herb is very low. In order to obtain useful quantities of przewalskinic acid A, the biotransformatin of salvianolic acid B from Salvia miltiorrhiza root (danshen in Chinese) into przewalskinic acid A was studied using a crude enzyme produced from Aspergillus oryzae D30s strain. The crude enzyme from the A. oryzae strain hydrolyzed salvianolic acid B into przewalskinic acid A and danshensu. The preparation afforded 31.3 g przewalskinic acid A (91.0 % purity) and 13.1 g danshensu (95 % purity) from 75 g salvianolic acid B. The preparation of przewalskinic acid A was therefore very successful with a yield of over 86 %, but the yield of danshensu was only 33 %. The product przewalskinic acid A was identified using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and NMR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24615145     DOI: 10.1007/s10295-013-1399-7

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  12 in total

Review 1.  Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use.

Authors:  Limin Zhou; Zhong Zuo; Moses Sing Sum Chow
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

2.  New dioscin-glycosidase hydrolyzing multi-glycosides of dioscin from Absidia strain.

Authors:  Yaoyao Fu; Hongshan Yu; Si Hui Tang; Xiangchun Hu; Yuanhao Wang; Bing Liu; Chenxu Yu; Fengxie Jin
Journal:  J Microbiol Biotechnol       Date:  2010-06       Impact factor: 2.351

3.  Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion.

Authors:  Li-juan Zhang; Lei Chen; Yin Lu; Jia-ming Wu; Bo Xu; Zhi-guang Sun; Shi-zhong Zheng; Ai-yun Wang
Journal:  Eur J Pharmacol       Date:  2010-07-11       Impact factor: 4.432

4.  A novel ginsenosidase from an Aspergillus strain hydrolyzing 6-O-multi-glycosides of protopanaxatriol-type ginsenosides, named ginsenosidase type IV.

Authors:  Dong-Ming Wang; Hong-Shan Yu; Jian-Guo Song; Yu-Feng Xu; Chun-Ying Liu; Feng-Xie Jin
Journal:  J Microbiol Biotechnol       Date:  2011-10       Impact factor: 2.351

5.  Effects of salvianolic acid a on oxidative stress and liver injury induced by carbon tetrachloride in rats.

Authors:  Zhi-Ming Wu; Tao Wen; Yu-Fen Tan; Yan Liu; Feng Ren; Hao Wu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-02       Impact factor: 4.080

6.  Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels.

Authors:  Francis Fu Yuen Lam; John Hok Keung Yeung; Kam Ming Chan; Penelope Mei Yu Or
Journal:  Vascul Pharmacol       Date:  2006-11-18       Impact factor: 5.773

7.  Purification and characterization of new special ginsenosidase hydrolyzing multi-glycisides of protopanaxadiol ginsenosides, ginsenosidase type I.

Authors:  Hongshan Yu; Chunzhi Zhang; Mingchun Lu; Fang Sun; Yaoyao Fu; Fengxie Jin
Journal:  Chem Pharm Bull (Tokyo)       Date:  2007-02       Impact factor: 1.645

Review 8.  Does Danshen improve disability after acute ischaemic stroke?

Authors:  F K-h Sze; F F Yeung; E Wong; J Lau
Journal:  Acta Neurol Scand       Date:  2005-02       Impact factor: 3.209

9.  Characterization of the radical scavenging and antioxidant activities of danshensu and salvianolic acid B.

Authors:  Guang-Rong Zhao; Heng-Ming Zhang; Ting-Xiang Ye; Zhi-Jun Xiang; Ying-Jin Yuan; Zhi-Xin Guo; Li-Bin Zhao
Journal:  Food Chem Toxicol       Date:  2007-07-04       Impact factor: 6.023

Review 10.  Salvia miltiorrhiza and ischemic diseases.

Authors:  X Y Ji; B K Tan; Y Z Zhu
Journal:  Acta Pharmacol Sin       Date:  2000-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.